INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
Non-Hodgkin's Lymphoma, Cancer
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma focused on measuring Lymphoma-Non Hodgkins, Phase II, Gemcitabine, Irinotecan
Eligibility Criteria
Inclusion Criteria: Patients with a histologic diagnosis of non-HIV related B-cell NHL or Hodgkins disease are eligible. Patients should have documented evidence of refractory or relapsed NHL or Hodgkins disease for inclusion. Patient should have received 1 or more prior chemotherapeutic regimens for relapse, and should have completed last course of treatment at least 3 weeks prior to enrollment. The patient must have bidimensionally measurable or evaluable disease. Age > 18 years. ECOG Performance status < 2 Informed consent. ANC > 1.5, platelet count > 100K, creatinine< 2.0, bilirubin < 3 Female patients must have a negative pregnancy test.
Sites / Locations
- Lovelace Sandia Health Systems Dept of Hematology
- University of New Mexico